U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Meditech Laboratories, Inc - 506537 - 12/06/2017
  1. Warning Letters

CLOSEOUT LETTER

Meditech Laboratories, Inc MARCS-CMS 506537 —

Recipient:
Meditech Laboratories, Inc

United States

Issuing Office:

United States

 

   

Black HHS-Blue FDA Logo

 

Division of Pharmaceutical Quality Operations IV
19701 Fairchild Road, Irvine, CA 92612-2506 
 
 

December 6, 2017

Michael B. Bitar, PharmD, Pharmacist-in-Charge
Meditech Laboratories, Inc.
3200 Polaris Ave Suite #27
Las Vegas, NV 89102

Dear Dr. Bitar:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (Reference No. CMS 506537) dated October 19, 2016. We acknowledge that your firm no longer produces sterile drug products. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. If you decide to resume production of drug products intended to be sterile, FDA strongly recommends that you undertake a comprehensive assessment of your operations, including facility design, and that you notify FDA prior to resuming sterile production. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Mark C. Saale
Acting Director, Compliance Branch
Division of Pharmaceutical Quality Operations IV 

Back to Top